FLOSEAL Hemostatic Matrix + Standard of care

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
82
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Knee Replacement Surgery

Conditions

Knee Replacement Surgery, Osteoarthritis

Trial Timeline

Sep 1, 2011 โ†’ Jan 1, 2013

About FLOSEAL Hemostatic Matrix + Standard of care

FLOSEAL Hemostatic Matrix + Standard of care is a approved stage product being developed by Baxter for Knee Replacement Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT01410240. Target conditions include Knee Replacement Surgery, Osteoarthritis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01410240ApprovedCompleted

Competing Products

20 competing products in Knee Replacement Surgery

See all competitors
ProductCompanyStageHype Score
LY2828360 + PlaceboEli LillyPhase 2
52
UBX0101 or placeboUnity BiotechnologyPre-clinical
15
UBX0101Unity BiotechnologyPhase 1
25
UBX0101Unity BiotechnologyPhase 2
44
UBX0101Unity BiotechnologyPhase 1
25
YH23537 + Celecoxib + YH23537 placeboYuhanPhase 2
52
YM150 + WarfarinAstellas PharmaPhase 2
52
ASP7962 + Naproxen + PlaceboAstellas PharmaPhase 2
52
Capsaicin Topical SolutionAstellas PharmaApproved
85
CGS-200-1 + CGS-200-5 + CGS-200 VehicleAstellas PharmaPhase 2
52
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + PlaceboSun PharmaceuticalPhase 2
52
Duloxetine + PlaceboShionogiPhase 3
77
DuloxetineShionogiPhase 3
77
V120083 + Naproxen + PlaceboShionogiPhase 2
52
ONO-4474 + Placebo matching ONO-4474Ono PharmaceuticalPhase 2
52
Duloxetine + PlaceboEli LillyPhase 3
77
Duloxetine (DLX) + Placebo (PLA)Eli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
Placebo + LY545694 49 mg + LY545694 105 mgEli LillyPhase 2
52
LY517717 + enoxaparinEli LillyPhase 2
52